

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/E5E1BAB9991FEN.html>

Date: July 2021

Pages: 332

Price: US\$ 2,000.00 (Single User License)

ID: E5E1BAB9991FEN

Abstracts

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide *Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2021*, provides an overview of the *Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)* pipeline landscape. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide *Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2021*, provides comprehensive information on the therapeutics under development for *Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)*, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The *Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)* pipeline guide also reviews of key players involved in therapeutic development for *Ebolavirus Infections (Ebola Hemorrhagic Fever)* and features dormant and

discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 8, 61, 26 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 13 and 8 molecules, respectively. Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease). The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise,

product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

ge.%li%Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) .%li%Classify potential new clients or partners in the target demographic.%li%Develop tactical initiatives by understanding the focus areas of leading companies.%li%Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutic s.%li%Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication t herapeutics.%li%De velop and design in-

licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Number of Products under Development by Universities/Institutes, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Universities/Institutes, 2021

Products under Development by Universities/Institutes, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Alkido Pharma Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AlphaVax Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AntoXa Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arisan Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Auro Vaccines LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Avipero Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Beijing Combio Pharmaceuticals Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Beijing Mabworks

Biotech Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Bharat Biotech Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioComo Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst

Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Biotron Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Celdara Medical LLC,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Chicago Biosolutions Inc,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Cocrystal Pharma Inc,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Collaborations
Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergent BioSolutions
Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergex Vaccines
Holding Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Etubics Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fab'entech SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fibroplate Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Flow Pharma Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fox Chase Chemical
Diversity Center Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Galactica Biotech Ltd,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gamaleya Federal
Research Center of Epidemiology and Microbiology, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gilead Sciences Inc,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Global BioLife Inc Ltd,
2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Greffex Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by H&P Labs Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by IDBiologics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals

Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Integral Molecular Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by IntelliStem Technologies Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Johnson & Johnson, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Mapp Biopharmaceutical Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Merck & Co Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Microbiotix Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Micropharm Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Novavax Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Oita University Institute of Advanced Medicine Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by OncXerna Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Orgenesis Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Ostrich Pharma USA Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Palisades Therapeutics, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by PanThera Biopharma LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Phelix Therapeutics LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Phoenix Biotechnology Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Public Health Vaccines LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Regeneron Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Riboscience LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by SAB Biotherapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Selva Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Soligenix Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by TFF Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Tiba Biotech LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Uvax Bio LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Vaccibody AS, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Vaxeal Holding SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Vir Biotechnology Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by XBiotech Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Xenothera SAS, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Yaso Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Yisheng Biopharma Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, 2021 (Contd..1)

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, 2021 (Contd..2)

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, 2021 (Contd..3)

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, 2021 (Contd..4)

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/E5E1BAB9991FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E5E1BAB9991FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

